Mechanism of immune-suppression causing Bevacizumab resistance in ovarian cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K20140
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: Kyoto University
• Principal Investigator: Abiko Kaoru 京都大学, 医学研究科, 助教 (20508246)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 卵巣癌 / 骨髄由来抑制性細胞 / 低酸素 / VEGF

Outline of Final Research Achievements

We explored the mechanisms of resistance to anti-VEGF therapy in ovarian cancer. In mouse models, anti-VEGF-antibody-resistant tumor showed larger hypoxic area and higher expression levels of GM-CSF. GM-CSF enhanced the production and immune-suppressive property of Myeloid Derived Suppressor Cells (MDSC) from myeloid cells. Our data indicated that targeting the hypoxia-induced cytokine, GM-CSF, may overcome the resistance to antiangiogenic therapy in ovarian cancer.

Free Research Field

医学